Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
UBS
McKinsey
Fish and Richardson
Dow
US Army
Cerilliant
Cantor Fitzgerald
Queensland Health
US Department of Justice

Generated: February 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,663,685

« Back to Dashboard

Which drugs does patent 8,663,685 protect, and when does it expire?

Patent 8,663,685 protects AMPYRA and is included in one NDA.

This patent has twenty-eight patent family members in sixteen countries.
Summary for Patent: 8,663,685
Title:Sustained release aminopyridine composition
Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
Inventor(s): Blight; Andrew R. (Mahopac, NY), Cohen; Ron (Irvington, NY)
Assignee: Acorda Therapeutics, Inc. (Ardsley, NY)
Application Number:13/187,158
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,663,685

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Acorda AMPYRA dalfampridine TABLET, EXTENDED RELEASE;ORAL 022250-001 Jan 22, 2010 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS) ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,663,685

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,007,826 Sustained release aminopyridine composition ➤ Try a Free Trial
8,354,437 Method of using sustained release aminopyridine compositions ➤ Try a Free Trial
8,440,703 Methods of using sustained release aminopyridine compositions ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,663,685

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia 2377536 ➤ Try a Free Trial
Slovenia 1732548 ➤ Try a Free Trial
Serbia 53371 ➤ Try a Free Trial
Serbia 51808 ➤ Try a Free Trial
Portugal 2377536 ➤ Try a Free Trial
Portugal 1732548 ➤ Try a Free Trial
Mexico PA06011648 ➤ Try a Free Trial
Luxembourg 92275 ➤ Try a Free Trial
Luxembourg 91933 ➤ Try a Free Trial
Japan 2015157861 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Johnson and Johnson
Cantor Fitzgerald
Argus Health
Baxter
Queensland Health
Federal Trade Commission
Fuji
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot